Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Expert Rev Anticancer Ther. 2021 Mar;21(3):241-250. doi: 10.1080/14737140.2021.1857243. Epub 2020 Dec 17.
: The prognosis of patients with HER2-positive early breast cancer has radically improved after the introduction of (neo)adjuvant anti-HER2 targeted therapy. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate combining the anticancer properties of the anti-HER2 agent trastuzumab and the antineoplastic cytotoxic drug DM1. After demonstrating to be an effective and safe treatment for patients with HER2-positive advanced breast cancer, the development of T-DM1 has moved to the early setting.: The aim of this review is to explore the current role of T-DM1 in the treatment landscape of HER2-positive early breast cancer, focusing specifically on the efficacy and safety data available in the adjuvant setting.: T-DM1 is an effective and safe treatment option in the adjuvant setting for patients with HER2-positive breast cancer without pathologic complete response after standard neoadjuvant chemotherapy plus anti-HER2 targeted therapy. With the availability of more effective anti-HER2 targeted agents, including T-DM1, there is an urgent need for more chemotherapy de-escalation research efforts in the early setting.
曲妥珠单抗-美坦新偶联物（T-DM1）是一种抗体-药物偶联物，结合了抗 HER2 药物曲妥珠单抗和抗肿瘤细胞毒性药物 DM1 的抗癌特性。在证明对 HER2 阳性晚期乳腺癌患者有效且安全后，T-DM1 的研发已转移到早期阶段。
本综述旨在探讨 T-DM1 在 HER2 阳性早期乳腺癌治疗领域中的当前作用，特别关注辅助治疗中可用的疗效和安全性数据。
在标准新辅助化疗加抗 HER2 靶向治疗后无病理完全缓解的 HER2 阳性乳腺癌患者的辅助治疗中，T-DM1 是一种有效且安全的治疗选择。随着更有效的抗 HER2 靶向药物（包括 T-DM1）的出现，早期治疗中迫切需要进行更多的化疗降阶研究。
